{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:55:08Z","timestamp":1778550908790,"version":"3.51.4"},"reference-count":52,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>The novel coronavirus, SARS-coV-2, which emerged in Wuhan in November 2019, has increasingly spread worldwide. More than 272 million cases of infection have been identified. COVID-19 has affected 223 countries and territories across the world. The principal target of the SARS-CoV-2 infection is the lower respiratory tract. Series of moderate to non-specific severe clinical signs and symptoms appear two to fourteen days after exposure to SARS-CoV-2 in patients with COVID-19 disease, including cough, breath deficiency, and at least two of these symptoms: headache, fever, chills, repeated rigor, myalgia, oropharyngitis, anosmia, and ageusia. No therapeutic agents have been validated to have substantial efficacy in the clinical care of COVID-19 patients in large-scale trials, despite worsening infected rates of COVID-19. Early clinical evidence from many sources suggests that treatment with famotidine may decrease COVID-19-related morbidity and mortality. The mechanism by which famotidine could improve the outcomes of COVID-19 is currently unknown. A more recent postulated mechanism is that the effect of famotidine is mediated by histamine-2 receptor antagonism or inverse agonism, inferring that the SARS-CoV-2, resulting in COVID-19 infection, at least partially leads to the abnormal release of histamine and perhaps dysfunction of mast cells.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871526522666220107125511","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T16:32:26Z","timestamp":1642523546000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic Status of Famotidine in COVID-19 Patients: A Review"],"prefix":"10.2174","volume":"22","author":[{"given":"Moein","family":"Mohseni","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Raissi","sequence":"additional","affiliation":[{"name":"Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasamin","family":"Sharifan","sequence":"additional","affiliation":[{"name":"Students Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimia","family":"Barikro","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasan","family":"Amiri","sequence":"additional","affiliation":[{"name":"Emam Reza Hospital, Sirjan School of Medical Sciences, Sirjan, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maedeh Sadat","family":"Mohseni","sequence":"additional","affiliation":[{"name":"Department of Engineering and Technology, Islamic Azad University, Sari Branch, Sari, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Raeisi","sequence":"additional","affiliation":[{"name":"Department of Nursing and Midwifery of Dezful Islamic Azad University, Dezful, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimia","family":"Masoumi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Khodakarami","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2382-550X","authenticated-orcid":true,"given":"Omid","family":"Raiesi","sequence":"additional","affiliation":[{"name":"Department of Parasitology, School of Allied Medical Sciences. Ilam University of Medical Sciences, Ilam, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"100925","DOI":"10.1016\/j.jbc.2021.100925","volume":"297","author":"Mukherjee R.","year":"2021","unstructured":"Mukherjee R.; Bhattacharya A.; Bojkova D.; Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. J Biol Chem 2021,297(2),100925","journal-title":"J Biol Chem"},{"key":"ref=2","author":"Tabanejad Z","year":"2021","unstructured":"Tabanejad Z; Darvish S; Borjian Boroujeni Z; Seroepidemiological study of novel coronavirus disease (CoVID-19) in Tehran, Iran. Infect Epidemiol Microbiol 7(2).2021","journal-title":"Infect Epidemiol Microbiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"633680","DOI":"10.3389\/fphar.2021.633680","volume":"12","author":"Malone R.W.","year":"2021","unstructured":"Malone R.W.; Tisdall P.; Fremont-Smith P.; COVID-19: Famotidine, histamine, mast cells, and mechanisms. Front Pharmacol 2021,12,633680","journal-title":"Front Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","volume":"53","author":"Lee P.I.","year":"2020","unstructured":"Lee P.I.; Hsueh P.R.; Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect 2020,53(3),365-367","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"Zhou P.","year":"2020","unstructured":"Zhou P.; Yang X.L.; Wang X.G.; A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020,579(7798),270-273","journal-title":"Nature"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jmii.2020.03.034","volume":"53","author":"Jean S.S.","year":"2020","unstructured":"Jean S.S.; Lee P.I.; Hsueh P.R.; Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect 2020,53(3),436-443","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","volume":"20","author":"Shi H.","year":"2020","unstructured":"Shi H.; Han X.; Jiang N.; Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis 2020,20(4),425-434","journal-title":"Lancet Infect Dis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=9","first-page":"3409","volume":"39","author":"Boopathi S.","year":"2021","unstructured":"Boopathi S.; Poma A.B.; Kolandaivel P.; Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn 2021,39(9),3409-3418","journal-title":"J Biomol Struct Dyn"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"Wiersinga W.J.","year":"2020","unstructured":"Wiersinga W.J.; Rhodes A.; Cheng A.C.; Peacock S.J.; Prescott H.C.; Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020,324(8),782-793","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00705-021-04956-9","volume":"166","author":"Dabbous H.M.","year":"2021","unstructured":"Dabbous H.M.; Abd-Elsalam S.; El-Sayed M.H.; Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol 2021,166(3),949-954","journal-title":"Arch Virol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijid.2021.03.048","volume":"106","author":"Murai Y.","year":"2021","unstructured":"Murai Y.; Kawasuji H.; Takegoshi Y.; A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. Int J Infect Dis 2021,106,33-35","journal-title":"Int J Infect Dis"},{"key":"ref=13","author":"Aleem A.","year":"2021","unstructured":"Aleem A.; Kothadia J.; Remdesivir 2021","journal-title":"Remdesivir"},{"key":"ref=14","author":"Cascella M.","year":"2021","unstructured":"Cascella M.; Rajnik M.; Aleem A.; Dulebohn S.; Di Napoli R.; Features, evaluation, and treatment of coronavirus (COVID-19) 2021","journal-title":"Features, evaluation, and treatment of coronavirus (COVID-19)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1002\/rmv.2270","author":"Chakraborty C.","year":"2021","unstructured":"Chakraborty C.; Bhattacharya M.; Sharma A.R.; Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Rev Med Virol 2021,e2270","journal-title":"Rev Med Virol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S2468-2667(21)00073-6","volume":"6","author":"Jewell B.L.","year":"2021","unstructured":"Jewell B.L.; Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages. Lancet Public Health 2021,6(5),e267-e268","journal-title":"Lancet Public Health"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1101\/2021.05.19.21257476","author":"Yang W","year":"2021","unstructured":"Yang W; Shaman J; Epidemiological characteristics of three SARS-CoV-2 variants of concern and implications for future COVID-19 pandemic outcomes. medRxiv 2021","journal-title":"medRxiv"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2100348","DOI":"10.2807\/1560-7917.ES.2021.26.16.2100348","volume":"26","author":"Funk T.","year":"2021","unstructured":"Funk T.; Pharris A.; Spiteri G.; Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: Data from seven EU\/EEA countries, weeks 38\/2020 to 10\/2021. Euro Surveill 2021,26(16),2100348","journal-title":"Euro Surveill"},{"key":"ref=19","first-page":"83","volume":"5","author":"Alexandar S.","year":"2021","unstructured":"Alexandar S.; Ravisankar M.; Kumar R.S.; Jakkan K.; A Comprehensive Review on Covid-19 Delta variant. Int J Clin Pharmacol Res 2021,5,83-85","journal-title":"Int J Clin Pharmacol Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2100636","DOI":"10.2807\/1560-7917.ES.2021.26.30.2100636","volume":"26","author":"Hetem\u00e4ki I.","year":"2021","unstructured":"Hetem\u00e4ki I.; K\u00e4\u00e4ri\u00e4inen S.; Alho P.; An outbreak caused by the SARS-CoV-2 Delta variant (B.1.617.2) in a secondary care hospital in Finland, May 2021. Euro Surveill 2021,26(30),2100636","journal-title":"Euro Surveill"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1016\/S0262-4079(21)01121-0","author":"Vaughan A.","year":"2021","unstructured":"Vaughan A.; Delta to dominate world 2021","journal-title":"Delta to dominate world"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1056\/NEJMc2114706","volume":"385","author":"Uriu K.","year":"2021","unstructured":"Uriu K.; Kimura I.; Shirakawa K.; Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum. N Engl J Med 2021,385(25),2397-2399","journal-title":"N Engl J Med"},{"key":"ref=23","year":"2021","unstructured":"Centers for disease control and prevention. Control CfD. Quarantine and Isolation. 2021"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"Salama C.","year":"2021","unstructured":"Salama C.; Han J.; Yau L.; Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021,384(1),20-30","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00011-020-01422-1","volume":"70","author":"Ennis M.","year":"2021","unstructured":"Ennis M.; Tiligada K.; Histamine receptors and COVID-19. Inflamm Res 2021,70(1),67-75","journal-title":"Inflamm Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/0016-5085(89)91489-3","volume":"97","author":"McCullough A.J.","year":"1989","unstructured":"McCullough A.J.; Graham D.Y.; Knuff T.E.; Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. Gastroenterology 1989,97(4),860-866","journal-title":"Gastroenterology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0002-9343(86)90600-5","volume":"81","author":"Vinayek R.","year":"1986","unstructured":"Vinayek R.; Howard J.M.; Maton P.N.; Famotidine in the therapy of gastric hypersecretory states. Am J Med 1986,81(4B),49-59","journal-title":"Am J Med"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0029-6465(22)00252-3","volume":"26","author":"Keithley J.K.","year":"1991","unstructured":"Keithley J.K.; Histamine H2-receptor antagonists. Nurs Clin North Am 1991,26(2),361-373","journal-title":"Nurs Clin North Am"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1053\/gast.1997.v112.pm9178671","volume":"112","author":"Hudson N.","year":"1997","unstructured":"Hudson N.; Taha A.S.; Russell R.I.; Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 1997,112(6),1817-1822","journal-title":"Gastroenterology"},{"key":"ref=30","author":"Nguyen K.","year":"2020","unstructured":"Nguyen K.; Dersnah G.D.; Ahlawat R.; Famotidine 2020","journal-title":"Famotidine"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12634","volume":"282","author":"Mukai K.","year":"2018","unstructured":"Mukai K.; Tsai M.; Saito H.; Galli S.J.; Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev 2018,282(1),121-150","journal-title":"Immunol Rev"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1152\/physrev.1997.77.4.1033","volume":"77","author":"Metcalfe D.D.","year":"1997","unstructured":"Metcalfe D.D.; Baram D.; Mekori Y.A.; Mast cells. Physiol Rev 1997,77(4),1033-1079","journal-title":"Physiol Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jiph.2021.08.022","volume":"14","author":"Almoosa Z.","year":"2021","unstructured":"Almoosa Z.; Saad M.; Qara S.; Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study. J Infect Public Health 2021,14(9),1247-1253","journal-title":"J Infect Public Health"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.14309\/ajg.0000000000000832","volume":"115","author":"Mather J.F.","year":"2020","unstructured":"Mather J.F.; Seip R.L.; McKay R.G.; Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. Am J Gastroenterol 2020,115(10),1617-1623","journal-title":"Am J Gastroenterol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0002-9343(86)90594-2","volume":"81","author":"Berlin R.G.","year":"1986","unstructured":"Berlin R.G.; Clineschmidt B.V.; Majka J.A.; Famotidine: An appraisal of its mode of action and safety. Am J Med 1986,81(4B),8-12","journal-title":"Am J Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"Anand K.","year":"2003","unstructured":"Anand K.; Ziebuhr J.; Wadhwani P.; Mesters J.R.; Hilgenfeld R.; Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science 2003,300(5626),1763-1767","journal-title":"Science"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=38","first-page":"9","volume":"34","author":"Kritas S.K.","year":"2020","unstructured":"Kritas S.K.; Ronconi G.; Caraffa A.; Gallenga C.E.; Ross R.; Conti P.; Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy. J Biol Regul Homeost Agents 2020,34(1),9-14","journal-title":"J Biol Regul Homeost Agents"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1365-2036.2005.02654.x","volume":"22","author":"Richter J.E.","year":"2005","unstructured":"Richter J.E.; Review article: The management of heartburn in pregnancy. Aliment Pharmacol Ther 2005,22(9),749-757","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1093\/cid\/ciaa330","volume":"71","author":"Giacomelli A.","year":"2020","unstructured":"Giacomelli A.; Pezzati L.; Conti F.; Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. Clin Infect Dis 2020,71(15),889-890","journal-title":"Clin Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jamaoto.2020.0832","volume":"146","author":"Eliezer M.","year":"2020","unstructured":"Eliezer M.; Hautefort C.; Hamel A.L.; Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg 2020,146(7),674-675","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FJC.0000000000000482","volume":"70","author":"Jean-Charles P.Y.","year":"2017","unstructured":"Jean-Charles P.Y.; Kaur S.; Shenoy S.K.; GPCR signaling via \u03b2-arrestin-dependent mechanisms. J Cardiovasc Pharmacol 2017,70(3),142","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","volume":"159","author":"Freedberg D.E.","year":"2020","unstructured":"Freedberg D.E.; Conigliaro J.; Wang T.C.; Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology 2020,159(3),1129-1131","journal-title":"Gastroenterology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1136\/gutjnl-2020-321852","volume":"69","author":"Janowitz T.","year":"2020","unstructured":"Janowitz T.; Gablenz E.; Pattinson D.; Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: A case series. Gut 2020,69(9),1592-1597","journal-title":"Gut"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2020.05.098","volume":"160","author":"Cheung K.S.","year":"2021","unstructured":"Cheung K.S.; Hung I.F.N.; Leung W.K.; Association between famotidine use and COVID-19 severity in Hong Kong: A territory-wide study. Gastroenterology 2021,160(5),1898-1899","journal-title":"Gastroenterology"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1007\/s10620-021-06872-z","volume":"66","author":"Sun C.","year":"2021","unstructured":"Sun C.; Chen Y.; Hu L.; Does Famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis. Dig Dis Sci 2021,66(11),3929-3937","journal-title":"Dig Dis Sci"},{"key":"ref=47","author":"Tomera K.","year":"2020","unstructured":"Tomera K.; Malone R.; Kittah J.; Hospitalized COVID-19 patients treated with celecoxib and high dose famotidine adjuvant therapy show significant clinical responses 2020","journal-title":"Hospitalized COVID-19 patients treated with celecoxib and high dose famotidine adjuvant therapy show significant clinical responses"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"Poluzzi E.","year":"2009","unstructured":"Poluzzi E.; Raschi E.; Moretti U.; De Ponti F.; Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009,18(6),512-518","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2165\/00003088-199121030-00003","volume":"21","author":"Echizen H.","year":"1991","unstructured":"Echizen H.; Ishizaki T.; Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991,21(3),178-194","journal-title":"Clin Pharmacokinet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1080\/15424065.2012.735134","volume":"9","author":"Vaughn C.J.","year":"2012","unstructured":"Vaughn C.J.; Drugs and lactation database: Lactmed. J Electron Resour Med Libr 2012,9(4),272-277","journal-title":"J Electron Resour Med Libr"},{"key":"ref=51","year":"2021","unstructured":"LIVERPOOL. U.O. COVID19-druginteractions. 2021"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00365528709090142","volume":"134","author":"Humphries T.J.","year":"1987","unstructured":"Humphries T.J.; Famotidine: A notable lack of drug interactions. Scand J Gastroenterol Suppl 1987,134(134),55-60","journal-title":"Scand J Gastroenterol Suppl"}],"container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220107125511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200096\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871526522666220107125511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:31:13Z","timestamp":1674477073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200096\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526522666220107125511","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e070122200096"}}